Long title
A phase III, randomized observer blinded, placebo-controlled, multi-center study, to evaluate safety and immunogenicity of the Chikungunya vaccine MV-CHIK in healthy adults
Date receipt dossier
EudraCT number
2019-0035000-12
Company / Sponsor
Themis Bioscience GmbH
Phase
III
Treated organism
Humans
Indication category
Infectious disease
Disease
Chikungunya fever
Therapeutic approach
Prevention
Genetic modification
Recombinant measles virus vaccine strain (Schwarz strain) expressing env (E1, E2, E3), capsid C en structural protein 6K from CHIKV
Method of transfer of nucleic acid of interest
Not applicable
Administered biological material
Recombinant measles virus vaccine strain (Schwarz strain) expressing E1, E2, E3, C, 6K protein from CHIKV
Route of administration
Intramuscular
Locations in Belgium
UZ Leuven, UZ Gent, U Antwerpen
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
MV-CHIK